Gavin Clark-Gartner
Stock Analyst at Evercore ISI Group
(2.03)
# 3,065
Out of 4,996 analysts
34
Total ratings
46.67%
Success rate
-6.66%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gavin Clark-Gartner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JSPR Jasper Therapeutics | Maintains: Outperform | $20 → $14 | $2.47 | +466.80% | 4 | Sep 22, 2025 | |
| ABBV AbbVie | Maintains: Outperform | $207 → $222 | $220.61 | +0.63% | 5 | Sep 22, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $77 → $89 | $72.76 | +22.32% | 3 | Aug 8, 2025 | |
| PRQR ProQR Therapeutics | Initiates: Outperform | $5 | $2.11 | +136.97% | 1 | Apr 29, 2025 | |
| MNMD Mind Medicine (MindMed) | Initiates: Outperform | $23 | $10.67 | +115.56% | 1 | Jan 28, 2025 | |
| CABA Cabaletta Bio | Downgrades: In-Line | $15 → $6 | $2.36 | +154.24% | 2 | Dec 20, 2024 | |
| ARGX argenx SE | Maintains: Outperform | $675 → $706 | $712.03 | -0.85% | 4 | Nov 21, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $179 → $170 | $18.36 | +825.93% | 9 | Nov 7, 2024 | |
| FHTX Foghorn Therapeutics | Initiates: Outperform | $20 | $4.86 | +311.52% | 1 | Aug 19, 2024 | |
| KRYS Krystal Biotech | Maintains: Outperform | $201 → $206 | $167.82 | +22.75% | 1 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $1.99 | +1,005.53% | 1 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $10 | $2.23 | +348.43% | 1 | May 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $60 | $32.68 | +83.60% | 1 | Oct 5, 2022 |
Jasper Therapeutics
Sep 22, 2025
Maintains: Outperform
Price Target: $20 → $14
Current: $2.47
Upside: +466.80%
AbbVie
Sep 22, 2025
Maintains: Outperform
Price Target: $207 → $222
Current: $220.61
Upside: +0.63%
Mirum Pharmaceuticals
Aug 8, 2025
Maintains: Outperform
Price Target: $77 → $89
Current: $72.76
Upside: +22.32%
ProQR Therapeutics
Apr 29, 2025
Initiates: Outperform
Price Target: $5
Current: $2.11
Upside: +136.97%
Mind Medicine (MindMed)
Jan 28, 2025
Initiates: Outperform
Price Target: $23
Current: $10.67
Upside: +115.56%
Cabaletta Bio
Dec 20, 2024
Downgrades: In-Line
Price Target: $15 → $6
Current: $2.36
Upside: +154.24%
argenx SE
Nov 21, 2024
Maintains: Outperform
Price Target: $675 → $706
Current: $712.03
Upside: -0.85%
Sarepta Therapeutics
Nov 7, 2024
Maintains: Outperform
Price Target: $179 → $170
Current: $18.36
Upside: +825.93%
Foghorn Therapeutics
Aug 19, 2024
Initiates: Outperform
Price Target: $20
Current: $4.86
Upside: +311.52%
Krystal Biotech
Aug 12, 2024
Maintains: Outperform
Price Target: $201 → $206
Current: $167.82
Upside: +22.75%
Oct 3, 2023
Initiates: Outperform
Price Target: $22
Current: $1.99
Upside: +1,005.53%
May 30, 2023
Maintains: Outperform
Price Target: $20 → $10
Current: $2.23
Upside: +348.43%
Oct 5, 2022
Maintains: Outperform
Price Target: $54 → $60
Current: $32.68
Upside: +83.60%